We are excited to announce that Biocytogen will attend the Future BioTech Expo August 19th–20th in Houston, TX. Bringing together leaders across biotechnology, pharmaceuticals, and life sciences, the expo is a valuable platform for discovering emerging technologies and building new collaborations.
What is the Future BioTech Expo?
The Future BioTech Expo is a global biotechnology conference where more than 2,500 industry leaders come together to shape the future of biotech. The event features keynote presentations, scientific sessions, and networking opportunities for attendees. Attendees will have the opportunity to exchange ideas, explore emerging technologies, and build partnerships across the global biotech community.
Event Overview
Date: August 19th - 20th, 2026
Venue: Hilton Houston North, 12400 Greenspoint Dr, Houston, TX 77060
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
